Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), filed a Form 4 on November 10, 2026, reporting the vesting of restricted stock units and a related sell-to-cover transaction on the same date.
Key Highlights
- RSU vesting: 10,937 restricted stock units converted to common stock on November 10, 2026, at $0.00 exercise price.
- Sell-to-cover: 4,442 shares were sold at an average price of $45.427 to satisfy statutory tax withholding obligations.
- Sale price range: Shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive.
- Remaining direct holdings: Nofi directly holds 6,495 shares of common stock following the reported transactions.
- Remaining RSUs: 32,813 restricted stock units remain beneficially owned directly, with an expiration date of November 10, 2035.
- RSU schedule: The RSUs vest in four equal annual installments beginning November 10, 2026.
CFO Nofi's RSU Vesting and Tax-Withholding Sale at Edgewise Therapeutics
According to the filing, Michael Nofi, the Chief Financial Officer of Edgewise Therapeutics, Inc., reported two transactions in common stock on November 10, 2026. First, 10,937 restricted stock units (RSUs) were converted to an equal number of shares of common stock via a transaction coded "M," at a price of $0.00. Immediately following this vesting event, Nofi held 10,937 shares directly.
The filing further discloses that 4,442 of those shares were then sold in a transaction coded "S" at an average price of $45.427 per share, with individual sale prices ranging from $45.165 to $45.57, inclusive. According to the filing's explanation of responses, this sale "represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs)" and "does not represent a discretionary sale by the Reporting Person." After these two transactions, Nofi's direct beneficial ownership of common stock stood at 6,495 shares.
In Table II, the filing reports that 10,937 RSUs were disposed of via the vesting conversion, leaving Nofi with 32,813 RSUs directly owned. The filing states that these RSUs were "granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026," with an expiration date of November 10, 2035. The Form 4 was signed by John R. Moore as Attorney-in-Fact for Michael Nofi.
What Was Disclosed
Edgewise Therapeutics CFO Michael Nofi disclosed the November 10, 2026 vesting of 10,937 RSUs into common stock and the sell-to-cover sale of 4,442 shares at an average of $45.427 to meet statutory tax obligations, leaving him with 6,495 shares and 32,813 RSUs.



Please wait processing your request...